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Abstract
Objective: To evaluate medication changes in hospitalised
elderly patients diagnosed with angina pectoris and to compare
the selection of medication with evidence-based treatment
guidelines.
Design: Review of medical notes and patient interview.
Setting: St. Luke’s Hospital, Malta; January - May 2001.
Subjects: 226 patients, aged 60 years or over, with a history
of chronic stable angina and a discharge diagnosis of angina.
Main outcome measures: Prevalence of use of
antiplatelet agents, lipid lowering agents, beta-blockers, calcium
channel blockers, nitrates, potassium channel openers and
cellular anti-ischaemic agents; presence of co-morbidities,
concurrent medication and adverse effects.
Results: Prior to discharge, 77% of patients were receiving
antiplatelet agents and 27% were receiving lipid lowering agents.
The most frequent anti-ischaemic agents used were nitrates
(97%) and second-generation dihydropyridine calcium channel
blockers (59%).  Beta-blockers were used in 31% of patients and
non-dihydropyridine calcium channel blockers were used in 4%
of patients.  Potassium channel openers (nicorandil) and cellular
anti-ischaemic agents (trimetazidine) were used in 5% and 19%
of patients respectively.
Of patients discharged on a single anti-ischaemic agent, 96%
were prescribed nitrates, while 64% of those on two agents were
prescribed nitrates and dihydropyridine calcium channel
blockers.  Beta-blockers, nicorandil and trimetazidine were
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generally used in conjunction with at least two other anti-
ischaemic agents. The major medication changes involved the
addition, or increase in dose, of amlodipine and isosorbide
dinitrate.  The major determinants affecting choice of
medication were age and co-morbidities.
Conclusion: Medication selection for chronic stable angina
was not in accordance with treatment guidelines.
Introduction
Various pharmacological agents are used in the medical
management of chronic stable angina pectoris either to alleviate
symptoms or to decrease the complications of the disease.  There
is strong evidence that the use of aspirin reduces the risk of
death and recurrent events in patients with coronary artery
disease (CAD)1 and is therefore recommended for all patients
in the absence of contraindications.2-4  Significant reductions in
mortality rate and major coronary events have been
demonstrated with the use of statins.5  Treatment guidelines
indicate that the use of statins is warranted when the LDL-
cholesterol level is greater than 3.0 mmol/L.2,3  Beta-blockers
have been shown to be effective in the prevention of long-term
angina symptoms and in the reduction of cardiovascular
morbidity and mortality.6,7  Beta-blockers are thus considered
as first-line agents in the management of chronic stable
angina2-4.  Non-dihydropyridine calcium channel blockers such
as diltiazem and verapamil are the preferred alternatives when
the use of beta-blockers is contraindicated.3,4  Although such
agents are effective in relieving symptoms, evidence of their
effectiveness in reducing morbidity and mortality is limited.
Long-acting dihydropyridine calcium channel blockers such as
amlodipine are suitable for providing long-term symptomatic
relief.  Although there is clinical trial evidence for efficacy in
symptom control, nitrates have not been shown to reduce
mortality in patients with CAD.  For this reason, nitrates are no
longer considered as the first choice for long-term treatment of
chronic stable angina. 2-4  Potassium channel openers have so
far been considered as appropriate for symptomatic relief,
however, results from a recent large-scale study show significant
reductions in morbidity and mortality with the use of
nicorandil.8  Recent guidelines are now recommending
angiotensin converting enzyme (ACE) inhibitors in patients with
significant CAD (by angiography or previous myocardial
infarction (MI)) who also have diabetes and/or left ventricular
systolic dysfunction.9  Cellular anti-ischaemic agents, such as
trimetazidine, increase cell tolerance to ischaemia.  The place
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of these agents in established guidelines for the management
of chronic stable angina is, however, unclear.
Treatment selection requires a comparison of clinical trial
evidence and the consideration of those factors that may make
one drug preferable to another in a particular patient.  The main
objectives of the study were to examine the medication changes
following hospitalisation of elderly patients diagnosed with
angina; to assess the influence of factors such as age, gender,
co-morbidities, concurrent medication, adverse effects and
compliance on drug selection; and to compare the selection of
medication with evidence-based treatment guidelines.
Methods
Study design
Patients admitted to St. Luke’s Hospital (Malta) with anginal
symptoms were screened according to the inclusion and
exclusion criteria of the study.  Information was obtained by
document review and patient interview following patient
consent.  Patients’ medical notes provided patient details, past
medical history, laboratory investigations, drug treatment on
admission, and other relevant information such as adverse
effects and compliance.  The medication prescribed on discharge
was noted from the medication sheet and the discharge letter.
A structured closed-question format was adopted for the
interview schedule.  Questions were asked with respect to
adverse effects, compliance to the administration and storage
of angina medication, and supply of medication.
Patient selection
The Admissions Register of the Emergency and Admissions
Department was screened three times weekly for patients
admitted with a presenting complaint of chest pain.  The
respective wards were visited and medical notes were consulted
in order to select patients.
Inclusion criteria
Patients of both sexes who were admitted during the period
January to May 2001, who (a) were 60 years or over; (b) had a
history of chronic stable angina; and (c) were diagnosed as
suffering from angina during the admission under review.
Exclusion criteria
(a) patients with an impression of angina in whom the
diagnosis was still unconfirmed at the time of discharge; (b)
patients initially diagnosed as having angina but later confirmed
to have suffered an MI during the admission reviewed; and (c)
patients who did not reside locally.
Time schedule
A pilot study was conducted during January 2001 with 15
patients (5% of the predicted study population).  The remainder
of the study population was recruited between February to May
2001.
Table 1: Patients with co-morbid conditions
Co-morbid condition Number (%)
of patients
Hypertension 147 (65)
Heart failure 108 (48)
Previous MI 56 (25)
Heart block 26 * (12)
Aortic stenosis 2 (1)
Diabetes mellitus 98 (43)
Asthma 11 (5)
Chronic obstructive pulmonary disease 13 (6)
Peripheral vascular disease 13 (6)
Peptic ulcer disease 7 (3)
Depression 17 (8)
*first degree atrioventricular block (1); right bundle branch block
(9); left bundle branch block (16)
Study population
A total of 226 patients, representing all the patients admitted
during the time period indicated and who met the selection
criteria, were included in the study.
Statistical analysis
The data obtained from the study was sorted using
Microsoft® Excel 97 SR-1 and analysed using Bio-Medical Data
Package (BMDP).
The primary analysis included an assessment of the changes
in drug and drug formulation as well as changes in dose and
dosage regimen, when comparing the medication schedule on
discharge with that on admission. The results were statistically
evaluated using the McNemar test for symmetry, with P values
of 0.05 or less considered statistically significant.  The chi-
square (χ2) test for linear trend was used to assess the use of a
drug/drug group in relation to the number of agents used with
P values of 0.05 or less considered statistically significant.
Analysis of potential predictors (including age, gender, co-
morbidities, concurrent drug treatment) for the use of the drug/
drug group was performed.  The results were statistically
evaluated using the χ2 test of association, with P values of 0.05
or less considered statistically significant.
Results
Male patients (n=133) represented 59% of admissions while
41% were female patients (n=93).  The age of the patients ranged
between 60 and 91 years, with a mean age of 72.3 years (SD
7.6).  The most common co-morbidities were hypertension,
heart failure and diabetes (Table 1).  There were 42 patients
(19%) admitted under the care of a consultant cardiologist, while
184 patients (81%) were admitted under the care of other
consultant physicians.
Figure 1 illustrates the extent of use of each agent on
admission and on discharge.  Statistically significant
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characteristics at the time of discharge were identified for
antiplatelet agents (mainly aspirin), lipid lowering agents
(mainly statins) and beta-blockers.  When patients with peptic
ulcer disease, epigastric pain associated with aspirin, or those
on concurrent warfarin or ticlopidine therapy were excluded,
the proportion of patients on aspirin was 93% on discharge.  A
significant negative association was evident for aspirin use and
age (>75years).  The association between aspirin use and gender,
physician specialty, history of MI, hypertension,
hyperlipidaemia and diabetes was not of statistical significance.
Age (≤75years), cardiology specialty, previous angioplasty and
history of MI were positively associated with the use of lipid
lowering agents.  No significant association was noted with
gender, previous coronary bypass or diabetes.  When patients
with chronic obstructive pulmonary disease or asthma were
excluded, the proportion of patients on beta-blockers was 35%
on discharge.  A significant negative association was evident
with beta-blocker use and age, heart block, heart failure,
peripheral vascular disease and digoxin use.  Although no
significant association between beta-blocker use and history of
MI was noted, when categorised according to the time period
(≤3years, >3years), a positive association was present in favour
of the shorter time period since the MI (Table 2).
The major medication changes involved the addition, or
increase in dose, of amlodipine and isosorbide dinitrate.
Figure 2 illustrates the extent of beta-blocker use on discharge
in relation to the number of anti-ischaemic agents prescribed
(P=0.000, χ2 for linear trend).  Similar trends were also evident
with the use of calcium channel blockers, potassium channel
openers and cellular anti-ischaemic agents.  Figure 3 illustrates
the components of treatment combinations on discharge.  The
most frequent combination of anti-ischaemic agents was that
of two agents in 102 (45%) patients, and in 65 (64%) of these
cases the combination involved nitrates and long acting
dihydropyridine calcium channel blockers.
Discussion
Factors which have been significantly associated with aspirin
use include male gender, patient age, history of MI,
hyperlipidaemia and care by cardiologist, all being positive
predictors.10-14  These and other potential predictors were tested
for in the study population.  Only with patient age was there a
significant association in that aspirin was used less frequently
in patients greater than 75 years of age.  Although aspirin therapy
in the most elderly patients may carry an increased risk of
complications, it is in this population that aspirin is likely to
have the greatest absolute benefit13.
Various trials have demonstrated the benefit of statins post-
MI.5,15,16  In the study population, a statistically significant
association was in fact present in the patient group having a
history of MI.  Lipid lowering agents were less commonly used
in patients older than 75 years of age, an expected finding when
considering that the local treatment protocol in use at the time
of the study did not suggest treatment with lipid lowering agents
Figure 2:  Percentage of patients using beta-blockers
and total number of concurrent anti-ischaemic agents
on discharge
Figure 1:  Percentage of patients using specific agents
on admission and on discharge
APA: antiplatelet agent; LLA: lipid lowering agent;
BB: beta-blocker; CCB1: non-dihydropyridine calcium channel
blocker; CCB2: long-acting dihydropyridine calcium channel
blocker; Nit: nitrate; Nic: nicorandil; Tri: trimetazidine
Figure 3:  Percentage of patients using each anti-
ischaemic agent and total number of concurrent anti-
ischaemic agents on discharge
BB : beta-blocker; CCB : calcium channel blocker; Nit : nitrate;
Nic : nicorandil;Tri : trimetazidine
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Table 2:  Characteristics associated with patients
receiving beta-blockers on discharge
Characteristic % of patients P   χ2 test for
on beta-blockers association
Sex
Male 36 0.73
Female 33
Age
≤75 years 43 0.001
>75 years 20
Physician specialty
Cardiology 45 0.10
Non-cardiology 32
Co-morbidities
Hypertension
No 26 0.06
Yes 39
Diabetes mellitus
No 35 0.81
Yes 33
Hyperlipidaemia
No 31 0.06
Yes 45
History of MI
No 35 0.90
Yes 34
≤3 years 52 0.05
>3 years 25
Heart block
No 37 0.05
Yes 15
Heart failure
No 46 0.0001
Yes 20
Peripheral vasc. dis.
No 37 0.006
Yes 0
Depression
          No 34 0.76
          Yes 38
Concurrent treatment
Digoxin
No 37 0.01
Yes 6
Amiodarone
No 36 0.06
Yes 9
CCBs
No 41 0.18
Yes 31
CCBs: Calcium channel blockers. Patients with chronic
obstructive pulmonary disease or asthma were excluded.
in this age group.  The recent large trials that have demonstrated
mortality benefit of cholesterol lowering with statins in CAD,
involved patients younger than 75 years of age.  It is likely,
however, that older patients would show similar benefits.18  An
increased likelihood of use of lipid lowering agents in males
(compared to females) with dyslipidaemia and CAD has been
reported.14,17  Such gender inequalities were not observed in the
study undertaken.
Despite strong evidence that beta-blockers improve survival,
the results of the study undertaken indicate that only a minority
of patients were taking this medication on admission and on
discharge.   Moreover, beta-blockers were not being used as
single agents but were more commonly used as adjunctive
treatment with two or more other anti-ischaemic agents,
suggesting that beta-blockers were not being used as first-line
agents.  The use of beta-blockers was significantly lower in
patients older than 75 years of age, a finding that has also been
observed in other studies.19    The decreased use of beta-blockers
in patients with heart failure was statistically significant.
Guidelines for the management of heart failure in fact
recommend the use of beta-blockers for stable, mild to moderate
heart failure caused by left ventricular systolic dysfunction.  In
this situation, the precaution to be taken is the use of low doses
in the initial period with slow titration.  Since no indication of
the grade of severity of heart failure was present in the medical
notes, any extent of underutilisation of beta-blockers could not
be evaluated.  The association between beta-blocker use and
history of MI was not statistically significant. Several studies
have reported the underutilisation of beta-blockers for
secondary prevention after MI.12,20  However, when the time
period since the MI was considered (≤3years, and >3years), the
relationship was significant in that beta-blockers were more
commonly used in the former group, a finding reported by other
investigators.19  In spite of the fact that beta-blockers are
considered to be of particular value in patients with
hypertension and CAD, use of beta-blockers in this patient group
did not achieve the statistical significance reported in similar
studies.19
Although the non-dihydropyridine calcium channel blockers
are considered preferable to dihydropyridine calcium channel
blockers for the management of chronic stable angina in patients
intolerant to beta-blockers, these agents were used in only a
small proportion of patients.  Conversely, long-acting
dihydropyridine calcium channel blockers were the second most
commonly used anti-ischaemic agents after nitrates.  The results
suggest that these agents, particularly amlodipine, were
considered as second line agents in combination with nitrates.
Long-acting nitrates were prescribed in the majority of
patients on admission as well as on discharge.  When
considering patients on monotherapy with anti-ischaemic
agents, there is a clear implication that nitrates were still the
preferred choice.
A number of limitations of the study were identified.  These
included incomplete documentation of information, inadequate
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patient knowledge, ungraded disease severity, readmission bias
and the effect of covariates.  Furthermore, the clinicians’ choice
of medication at the time of discharge might have been affected
by investigations or interventions then pending.
Conclusion
The results of the study indicate that nitrates were still
considered as the most appropriate first-line agents in the
management of chronic stable angina.  Second generation
dihydropyridine calcium channel blockers were considered as
the most appropriate second line agents.  Despite the evidence
and recommendations in treatment guidelines favouring the use
of beta-blockers as first-line agents, the results suggest that these
agents were underutilised.  Furthermore, non-dihydropyridine
calcium channel blockers, which are recommended as the
alternative to beta-blockers, were hardly used at all.  The high
frequency of aspirin use, on the other hand reflected appropriate
management.  The appropriateness of use of lipid lowering
agents could not be fully assessed because of the relative
unavailability of lipid levels, although the latter fact in itself
suggests a possible underutilisation of these agents.
A number of predictors indicating inappropriate under-use
of specific medications were identified.  Of particular importance
was age in the case of aspirin, lipid lowering agents and beta-
blockers, and heart failure in the case of beta-blockers.
In general, the findings of the study suggest that the
management of chronic stable angina was not always in
accordance with evidence-based treatment guidelines, and
indicates a substantial need for optimising the medical
management of this disease.
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